0000000000653498

AUTHOR

Nicola Frisina

showing 5 related works from this author

Treatment adherence and QoL with intermittent PTH therapy: Results from a multicentre Italian study after 6 months

2011

Pediatricsmedicine.medical_specialtyHistologyPhysiologyTreatment adherencebusiness.industryEndocrinology Diabetes and MetabolismmedicinebusinessBone
researchProduct

Improvement of quality of life during treatment with anabolic therapy: Results of a multicenter study

2012

Efficacy and safety of daily treatment with parathyroid hormone were evaluated in a typical Italian population with severe post-menopausal osteoporosis eligible to anabolic treatment (Nota 79 AIFA). Materials and methods: 204 ambulatory female patients (median age: 72.6±8.3 years; height: 155.3±6.5 cm; weight: 61.1±11.9 Kg) with severe post-menopausal osteoporosis have been enrolled in this study accordingly to summary of product characteristics and Italian reimbursement criteria for osteoporosis drugs (Nota 79 AIFA), between January 2008 and April 2009 (Last Patient Out: October 2010). 146 (71.57%) out of these patients completed the study.6 visits were planned in the study protocol: basel…

medicine.medical_specialtyHistologyAnabolismosteoporosis PTH Qualeffo QolPhysiologybusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaEndocrinology Diabetes and MetabolismQuality of life (healthcare)Multicenter studymedicineIntensive care medicinebusinessBone
researchProduct

Intravenous recombinant erythropoietin does not lead to an increase in cerebrospinal fluid erythropoietin concentration

2000

No abstract

Adultmedicine.medical_specialtyUltrasonography Doppler Transcranialmedicine.medical_treatmentSkull NeoplasmsElectrolytesIntraoperative PeriodCerebrospinal fluidPharmacokineticsInternal medicinemedicineHumansPulseRecombinant erythropoietinErythropoietinTransplantationChemotherapybusiness.industrySettore MED/27 - NeurochirurgiaErythropoietin transcranial dopplerRecombinant ProteinsEndocrinologyCytokineBlood-Brain BarrierNephrologyErythropoietinCerebrovascular CirculationInjections IntravenousIntravenous recombinant erythropoietin; cerebrospinal fluid; erythropoietin concentration.Femalebusinessmedicine.drug
researchProduct

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

2004

Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…

musculoskeletal diseasesMalemedicine.medical_specialtyDeoxypyridinolineTime FactorsBicalutamideAntineoplastic Agents HormonalEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrologyBone and BonesAndrogen deprivation therapychemistry.chemical_compoundProstate cancerAbsorptiometry PhotonBone DensityMedicineNeridronic acidHumansOrthopedics and Sports MedicineAmino AcidsAgedCholecalciferolTriptorelin PamoateDiphosphonatesbusiness.industryProstatic NeoplasmsAndrogen AntagonistsBisphosphonatemedicine.diseaseAlkaline PhosphataseAndrogen deprivation therapy; Bisphosphonates; Neridronate; Osteoporosis; Prostate cancer; Absorptiometry Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents Hormonal; Bone Density; Bone and Bones; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate; SurgerySurgerychemistryAndrogensOsteoporosisCalciumbusinessCholecalciferolmedicine.drugJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
researchProduct

Preventing bone loss during androgen deprivation therapy for prostate cancer: Early experience with neridronate

2005

Abstract Objective: Androgen-deprivation therapy (ADT) is the usual treatment for locally advanced or metastatic prostate cancer. Osteoporosis is a common complication of ADT. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate to prevent bone loss during androgen ablation. Methods: Sixty patients with prostate cancer and osteoporosis were enrolled and randomly assigned to 2 different treatment regimes: group A (30 patients) treated with maximum androgenic blockage (MAB), and group B (30 patients) treated with bicalutamide 150mg. Each group was divided in 2 subgroups A1–A2 and B1–B2. All patients received calcium and cholecalciferol supplements …

Malemusculoskeletal diseasesmedicine.medical_specialtyDeoxypyridinolineBone densityBicalutamideUrologymedicine.medical_treatmentOsteoporosisUrologyImmunoenzyme TechniquesTosyl CompoundsAndrogen deprivation therapyProstate cancerchemistry.chemical_compoundAbsorptiometry PhotonBone DensityNitrilesmedicineHumansNeridronic acidAnilidesTestosteroneAmino AcidsVitamin DChromatography High Pressure LiquidAgedAged 80 and overDiphosphonatesEstradiolbusiness.industryProstatic NeoplasmsAndrogen AntagonistsPhosphorusBisphosphonatemedicine.diseaseSurgeryTreatment OutcomechemistryParathyroid HormoneOsteoporosisCalciumDrug Therapy CombinationbusinessBiomarkersFollow-Up Studiesmedicine.drug
researchProduct